Abstract
Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 291-299 |
| Number of pages | 9 |
| Journal | Expert Review of Clinical Immunology |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2009 |
Fingerprint
Keywords
- Biologic response modifier
- Disease-modifying antirheumatic drug
- Methotrexate
- Rheumatoid arthritis
- TNF inhibitor
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Discussion : DMARDs and biologic therapies in the management of inflammatory joint diseases. / Vaz, Austin; Lisse, Jeffrey R; Rizzo, Warren; Albani, Salvatore.
In: Expert Review of Clinical Immunology, Vol. 5, No. 3, 2009, p. 291-299.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Discussion
T2 - DMARDs and biologic therapies in the management of inflammatory joint diseases
AU - Vaz, Austin
AU - Lisse, Jeffrey R
AU - Rizzo, Warren
AU - Albani, Salvatore
PY - 2009
Y1 - 2009
N2 - Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.
AB - Therapy for inflammatory joint diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, includes various conventional disease-modifying antirheumatic drugs (DMARDs). These therapeutic agents are termed DMARDs because they have the potential to reduce or prevent joint damage and preserve joint integrity and function. Conventional DMARDs are used as monotherapy or in combination and include methotrexate, leflunomide, azathioprine, ciclosporin, hydroxychloroquine, sulfasalazine, gold and minocycline. Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved for use in inflammatory joint diseases are TNF inhibitors, T-cell modulators and B-cell depleters. They have all been shown to have clinical efficacy and are able to retard structural damage. However, all current immune-modulating therapies also have potential side effects, and the decision to use a particular agent for treatment should be based on a thorough discussion of the benefits and risks with the patient. Newer biologic response modifiers and other immunologic therapies are currently being developed for the treatment of inflammatory joint diseases and are discussed in this review.
KW - Biologic response modifier
KW - Disease-modifying antirheumatic drug
KW - Methotrexate
KW - Rheumatoid arthritis
KW - TNF inhibitor
UR - http://www.scopus.com/inward/record.url?scp=77649107244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77649107244&partnerID=8YFLogxK
U2 - 10.1586/eci.09.14
DO - 10.1586/eci.09.14
M3 - Article
C2 - 20477007
AN - SCOPUS:77649107244
VL - 5
SP - 291
EP - 299
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
IS - 3
ER -